Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial

Heart Failure

Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial

JAMA Cardiol.

Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA, Mann DL, Margulies KB, McNulty SE, Mentz RJ, Redfield MM, Tang WHW, Whellan DJ, Shah M, Desvigne-Nickens P, Hernandez AF, Braunwald E; National Heart Lung and Blood Institute Heart Failure Clinical Research Network

doi: 10.1001/

Heart Failure

Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial

JACC Heart Fail.

Cerbin LP, Ambrosy AP, Greene SJ, Armstrong PW, Butler J, Coles A, DeVore AD, Ezekowitz JA, Hernandez AF, Metra M, Starling RC, Tang W, Teerlink JR, Voors AA, Wu A, O'Connor CM, Mentz RJ

doi: 10.1016/j.jchf.2018.01.018.

Heart Failure

Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial

JAMA Cardiol.

DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty H, McCague K, Rocha R, Velazquez EJ, PIONEER-HF Investigators.

doi: 10.1001/jamacardio.2019.4665.

Heart, Artery and Coronary DiseasesHeart Failure

Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)

Eur J Heart Fail.

Rickenbacher P, Kaufmann BA, Maeder MT, Bernheim A, Goetschalckx K, Pfister O, Pfisterer M, Brunner-La Rocca HP; TIME-CHF Investigators

doi: 10.1002/ejhf.798.

Heart Failure

PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial

Am Heart J.

Mentz RJ, DeVore AD, Tasissa G, Heitner JF, Piña IL, Lala A, Cole RT, Lanfear DD, Patel CB, Ginwalla M, Old W, Salacata AS, Bigelow R, Fonarow GC, Hernandez AF

doi: 10.1016/j.ahj.2019.12.024.

Heart Failure

Management of cardiogenic shock in acute decompensated chronic heart failure: The ALTSHOCK phase II clinical trial

Am Heart J.

Morici N, Oliva , Ajello S, Stucchi M, Sacco A, Cipriani MG, De Bonis M, Garascia A, Gagliardone MP, Melisurgo G, Russo CF, La Vecchia C, Frigerio M, Pappalardo F

doi: 10.1016/j.ahj.2018.07.009.

Heart Failure

The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics

Eur J Heart Fail.

McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, DAPA-HF Committees and Investigators

doi: 10.1002/ejhf.1548.

Heart Failure

Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial

Eur J Heart Fail.

Ferreira JP, Lam CSP, Anker SD, Mehra MR, van Veldhuisen DJ, Byra WM, La Police DA, Cleland JGF, Greenberg B, Zannad F

doi: 10.1002/ejhf.2003.

Heart Failure

Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure

JAMA Cardiol.

Simpson J, Jhund PS, Lund LH, Padmanabhan S, Claggett BL, Shen L, Petrie MC, Abraham WT, Desai AS, Dickstein K, Køber L, Packer M, Rouleau JL, Mueller-Velten G, Solomon SD, Swedberg K, Zile MR, McMurray JJV

doi: 10.1001/jamacardio.2019.5850.

Related content

Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial

Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial

Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial

Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)

PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial

Management of cardiogenic shock in acute decompensated chronic heart failure: The ALTSHOCK phase II clinical trial

The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics

Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial

Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure